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Focal nodular hyperplasia (FNH) is a common benign hepatic tumor, usually discovered incidentally in young women (1, 2). While most FNH are confidently diagnosed on the basis of characteristic imaging appearance, they may sometimes mimic other liver 
masses, resulting in reduced diagnostic confidence by the radiologist (3, 4) and therefore in 
further test ordering and increased patient anxiety. An appropriate preoperative diagnosis 
is therefore essential in order to warrant conservative management. 
Liver-specific MRI contrast agents are being increasingly used in clinical practice. Those 
currently available are gadobenate dimeglumine (MultiHance, Bracco) and gadoxetate di-
sodium (Primovist, Bayer Schering Pharma; Eovist, Bayer Healthcare Pharmaceuticals). After 
injection, these agents circulate in the vascular system and diffuse into the interstitium, 
thus allowing the acquisition of multiple phases (i.e., arterial and portal venous phases). 
Moreover, after an interval time that varies between the two agents, these are uptaken by 
functioning (i.e., nondamaged) hepatocytes of both hepatic parenchyma and hepatocellu-
lar lesions on hepatobiliary phase, providing further insights for the noninvasive character-
ization of focal liver lesions (1, 5). Approximately 50% of gadoxetate disodium is uptaken 
by normally functioning liver hepatocytes, whereas gadobenate dimeglumine uptake by 
hepatocytes accounts for only 3%–5% of the injected dose (1, 5). 
Hepatobiliary MRI contrast agents have been successfully used for the diagnosis of FNH 
lesions, which are typically isointense or hyperintense to the surrounding parenchyma on 
hepatobiliary phase (6, 7). Due to the different percentage of hepatocellular uptake of the 
PURPOSE 
We aimed to qualitatively and quantitatively compare the enhancement pattern of focal nodu-
lar hyperplasia after gadobenate dimeglumine and gadoxetate disodium injection in the same 
patient. 
METHODS
1.5 T magnetic resonance imaging (MRI) examinations of 16 patients with 21 focal nodular hy-
perplasias studied after the injection of both contrast media were evaluated. Both MRI studies 
were performed in all patients. A qualitative analysis was performed evaluating each lesion in 
all phases. For quantitative analysis we calculated signal intensity ratio, lesion-to-liver contrast 
ratio and liver parenchyma signal intensity gain on hepatobiliary phase. Statistical analysis was 
performed with the Wilcoxon sign-rank test for clustered paired data and the McNemar test for 
paired frequencies. A P value < 0.05 was considered statistically significant. 
RESULTS
At qualitative analysis no statistically significant differences were evident during any of the con-
trast-enhanced phases. Signal intensity ratio (P = 0.048), lesion-to-liver contrast ratio (P = 0.032) 
and liver parenchyma signal intensity gain (P = 0.012) were significantly higher on hepatobiliary 
phase after gadoxetate disodium injection. 
CONCLUSION
There were no significant differences in the MRI findings of focal nodular hyperplasia after the 
injection of a weight-based dose of either gadobenate dimeglumine or gadoxetate disodium.
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two agents, we hypothesized that imaging 
features of FNH could be different when ei-
ther contrast agent is used. 
Therefore, the aim of our study was to 
qualitatively and quantitatively compare 
the enhancement pattern of FNH after the 
injection of a weight-based dose of gado-
benate dimeglumine and gadoxetate di-
sodium intravenous injection in the same 
patient studied at a single institution. 
Methods
Patients and lesions 
This study followed the Declaration of 
Helsinki principles. Institutional review 
board approval was not deemed neces-
sary due to the retrospective nature of this 
study, and informed consent was waived.
We performed a search for the string 
terms “focal nodular hyperplasia” or “FNH” 
in the radiology databases at our institution 
in a five-year span and identified 140 con-
secutive patients. Sixteen of these patients 
had more than one MRI study performed 
with both gadobenate dimeglumine and 
gadoxetate disodium and formed our final 
study population. 
Our study population consisted of 13 
women and three men (age range, 30–63 
years; mean age, 39.9±9.2 years) with a to-
tal of 21 FNHs (size range, 0.9–4.4 cm; mean 
size, 2.2±1 cm). Twelve patients had one 
lesion, three patients had two lesions, and 
one patient had three lesions.
None of these patients had history of 
chronic liver disease or malignancy. The 
mean interval time between MRI examina-
tions in the same patient was 404.8±327.3 
days (range, 130–1495 days). 
No changes have been observed regard-
ing the size of FNHs during imaging fol-
low-up.
Standard of reference 
Diagnosis of FNH on contrast-enhanced 
MRI was based on the presence of all of 
the following criteria: a) round or oval 
shape; b) signal intensity similar to that of 
the surrounding liver on T1-weighted and 
T2-weighted sequences; c) homogeneity; 
d) strong enhancement on arterial phase 
with no subsequent washout. Washout 
was defined as lower signal intensity in 
comparison to the surrounding liver on 
either portal venous or delayed phase 
on gadobenate dimeglumine-enhanced 
MRI and on portal venous phase only on 
gadoxetate disodium-enhanced MRI; e) 
absence of capsule. Capsule was defined 
as a continuous rim surrounding the FNH 
lesions, showing higher signal intensity 
in comparison to the surrounding liver 
on either portal venous or delayed phase 
on gadobenate dimeglumine-enhanced 
MRI or on portal venous phase only on 
gadoxetate disodium-enhanced MRI and 
lower signal intensity in comparison to the 
surrounding liver on hepatobiliary phase 
after gadobenate dimeglumine or gadox-
etate disodium-enhanced imaging. A rim 
of peripheral, hyperintensity of the outer 
portion of FNH on hepatobiliary phase 
with either contrast agent was not con-
sidered as a capsule, but rather as one of 
the possible patterns of enhancement of 
FNH in the hepatobiliary phase (8). Pres-
ence of a central scar was not considered 
mandatory because of the low sensitivity 
and specificity for the diagnosis of FNH (9, 
10). The MRI protocol used in both exam-
inations is detailed as follows. 
MRI technique 
MRI was performed with a 1.5 T scanner 
(Signa Excite, General Electric Healthcare) 
by using a dedicated abdominal multichan-
nel phased-array coil. The precontrast pro-
tocol is summarized in Table 1. 
Gadobenate dimeglumine-enhanced MRI
A multiphasic dynamic study was ob-
tained after the administration of 0.2 mL/kg 
of gadobenate dimeglumine (MultiHance, 
Bracco Diagnostics) injected at a flow rate 
of 2 mL/s and flushed by 20 mL of saline 
solution using an automatic MRI-compati-
ble injector (Medrad Spectris Solaris EP MR 
Injection System, Bayer Healthcare). Images 
were acquired using automated bolus de-
tection technique (Smart-prep technique, 
GE Healthcare) during the arterial (16 s 
after bolus detection), portal venous and 
delayed phase (60 and 180 s after contrast 
injection, respectively). The dynamic study 
was followed by an acquisition during the 
hepatobiliary phase obtained 2 hours after 
the injection of contrast material. 
Main points
• At qualitative analysis, dynamic and hepato-
biliary enhancement patterns of FNH do not 
significantly differ when a weight-based dose 
of either gadobenate dimeglumine or gadox-
etate disodium is injected. 
• At quantitative analysis, focal nodular hy-
perplasia signal intensity, liver parenchyma 
signal intensity and lesion-to-liver contrast 
ratio were stronger after gadoxetate disodi-
um injection in comparison with gadobenate 
dimeglumine injection during the hepatobi-
liary phase.
• Gadobenate dimeglumine and gadoxetate 
disodium are equally valuable for the diag-
nosis of FNH, but gadobenate dimeglumine 
is more time consuming than gadoxetate di-
sodium.





(mm) Matrix NEX Slices/time (s)
Breath-hold T2W SSFSE 946/182.7 62.5 40×40 6/1 384×224 0.57 22/20
Respiratory triggered T2W FSE 50 40×40 6/1 256×224 4 22/180
Respiratory triggered T2W FSE with FS 4286/83.7 50 40×40 6/1 320×224 4 22/210
Breath-hold T1W (FSPGR) (in and out of phase) 150/4.2/2.0 62.5 40×40 4.4/1 256×192 1 44/31 
(2 acquisitions)
Breath-hold T1W 3D SPGR with FS 4.2/2.0 62.5 40×40 4.4/2.2 overlap 320×192 0.71 22/20
TR/TE, repetition time/echo time; FOV, field of view; NEX, number of excitations; T2W, T2-weighted imaging; SSFSE, single shot fast spin-echo; FSE, fast spin-echo; FS, fat 
suppression; T1W, T1-weighted imaging; FSPGR, fast spoiled gradient echo; 3D, three-dimensional.
Gadoxetate disodium-enhanced MRI 
For the gadoxetate disodium-enhanced 
MRI, the two T2-weighted respiratory trig-
gered sequences were acquired after the 
completion of the triphasic dynamic ga-
doxetate disodium-enhanced study. The 
triphasic dynamic contrast-enhanced study 
was obtained after the administration of 
an intravenous bolus of 0.1 mL/kg of ga-
doxetate disodium (Primovist or Eovist; 
Bayer Healthcare) injected at a flow rate 
of 1 mL/s and flushed by 20 mL of sterile 
saline solution using the same automatic 
MRI-compatible injector. The scanning de-
lay for triphasic dynamic three dimensional 
(3D) gradient-echo imaging was 18 s after 
the automated bolus detection for the ar-
terial phase, 60 s after the start of contrast 
injection for portal venous and 180 s for 
transitional phase, respectively. The dynam-
ic study was followed by a hepatobiliary 
phase obtained 20 min after the injection 
of contrast material. 
All examinations were digitally stored 
and evaluated using our institutional Pic-
ture Archiving and Communication System 
(PACS - Impax, Agfa-Gevaert) in order to 
perform both qualitative and quantitative 
analysis. 
Image interpretation 
Two experienced radiologists, both with 
more than 10 years of experience in liver 
MRI, randomly reviewed in consensus all 
images on PACS. None of the two readers 
were involved in the scanning, and they 
were blinded to any patient-related infor-
mation and to the type of contrast agent, 
while they were aware of the diagnosis. 
Four consecutive randomized interpreta-
tion sessions with a seven-day interval to 
avoid recall bias were held to complete the 
review process of all scans. 
Qualitative analysis
The two readers evaluated each lesion 
with respect to the surrounding liver pa-
renchyma in all sequences before and 
after contrast medium administration as: 
1) hypointense; 2) slightly hypointense; 
3) isointense; 4) slightly hyperintense; 5) 
hyperintense. Readers defined each lesion 
as homogeneous or heterogeneous after 
contrast-media injection. Signal intensity 
was considered homogeneous when the 
lesion enhanced to the same degree in all 
its parts, with the exception of the central 
scar, when present. A ring-like enhance-
ment pattern was defined as a lesion 
showing a peripheral iso-hyperintense 
rim surrounding a central hypointense 
portion during the hepatobiliary phase. 
Finally, readers described the signal in-
tensity of the central scar on the different 
sequences.
Quantitative analysis 
Quantitative analysis was performed in 
consensus by two different radiologists 
not involved in the qualitative analysis. Sig-
nal intensities (SI) of the liver parenchyma 
and FNH lesions were measured in each 
patient on all breath-hold 3D fat-saturated 
T1-weighted sequences before and after 
contrast medium administration. Regions 
of interest (ROIs) were positioned on the 
right and left liver lobes avoiding vessels, 
and a mean value was calculated. Then a 
ROI was drawn on the lesion, as large as 
possible, manually following its borders in 
all precontrast and postcontrast T1-weight-
ed MRI sequences, including hepatobiliary 
specific phase for both contrast media. All 
ROIs were positioned at comparable slice 
levels and at identical positions for each 
sequence. SI ratio (SIR, %) was calculat-
ed for each FNH in all contrast-enhanced 
T1-weighted sequences using the following 
formula: 
           SI post– SI pre
SIRFNH (%) =  ×100 
                 SIpre 
where SIpost is SI measured on contrast-en-
hanced phases, and SIpre is SI measured on 
precontrast images. Lesion-to-liver contrast 
ratio was also calculated using the follow-
ing formula: 
    SI FNH – SI liver
CR FNH-to-liver (%) =  ×100 
    SI FNH + SI liver 
where SIFNH is lesion SI and SIliver is liver SI, 
both measured on the same contrast-en-
hanced phases. 
In addition, liver parenchyma SI gain was 
evaluated for hepatobiliary phase as fol-
lows: 
    
     SI hepatocyte phase - SI precontrast
SI gain =   ×100 
  SI precontrast 
Finally, a relationship between central 
scar detection and lesion size was also eval-
uated. 
Statistical analysis 
Data were expressed as counts and per-
centage for qualitative variables and as 
medians and interquartile range for quan-
titative variables. The dependencies among 
multiple lesions within the same patient 
were considered explicitly in the statis-
tical analysis. With respect to qualitative 
evaluation, the McNemar test for paired 
frequencies was used in order to evaluate 
statistically significant differences between 
gadobenate dimeglumine and gadoxetate 
disodium for each postcontrast phase af-
ter both contrast media administration. 
With respect to quantitative evaluation, 
the Wilcoxon sign-rank test for clustered 
paired data was used in order to assess sta-
tistically significant differences between 
gadobenate dimeglumine and gadoxetate 
disodium patterns (11, 12). Statistical anal-
ysis was performed using the R software 
(https://cran.r-project.org). The Wilcoxon 
sign-rank test for clustered data was per-
formed using the clusrank package running 
in the R environment. A P value < 0.05 was 
considered statistically significant. 
Results 
All lesions were round or oval in shape. 
On precontrast T1-weighted images, 15 out 
of 21 FNHs (71%) were slightly hypointense, 
whereas the remaining six (29%) were re-
spectively isointense (n=3) and slightly hy-
perintense due to surrounding hypointense 
fatty liver (n=3). On T2-weighted images, 18 
of 21 (86%) were slightly hyperintense and 
the remaining three (14%) were isointense. 
After injection of either gadobenate di-
meglumine or gadoxetate disodium, all le-
sions (100%) were homogeneously hyper-
vascular in the arterial phase.
All (n=21, 100%) FNHs were iso-hyperin-
tense 180 s after both gadobenate dimeglu-
mine and gadoxetate disodium injection. 
On hepatobiliary phase, lesions showed 
uptake of contrast medium and were ho-
mogeneously iso-hyperintense in 17 of 21 
cases (81%) after gadobenate dimeglumine 
and in 16 of 21 cases (76%) after gadoxetate 
disodium (Fig. 1). 
A ring of peripheral enhancement sur-
rounding a central hypointense portion 
was noted in 4 (19%) and 5 (24%) cases 
after gadobenate dimeglumine and ga-
doxetate disodium administration, respec-
tively (Fig. 2; Table 2). No statistically signif-
icant differences were evident in contrast 
enhancement patterns between the two 
contrast media during the arterial (P = 1.0), 
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portal-venous (P = 0.416), 180 s (P = 0.416), 
and hepatobiliary (P = 0.199) phases. 
No central scar was detected in 7 of 21 
FNHs (33%) after injection of either gado-
benate dimeglumine or gadoxetate diso-
dium. 
A central scar was noted after both 
gadobenate dimeglumine and gadoxetate 
disodium in 9 FNHs (43%), only after gado-
benate dimeglumine in 4 cases (19%) and 
only after gadoxetate disodium in one case 
(5%). 
In particular:
In the arterial phase: not evident (n=1) or hy-
pointense (n=13) after injection of either gado-
benate dimeglumine or gadoxetate disodium;
In the portal-venous and/or at 180 s: 
a) hypointense (n=9) and hyperintense 
Figure 1. a–f. Focal nodular hyperplasia (FNH) in a 30-year-old woman. After injection of gadobenate dimeglumine (a–c), T1-weighted 3D gradient echo 
fat-saturated magnetic resonance image obtained in the arterial phase (a) shows a strongly and homogeneously hypervascular 1.8 cm lesion (arrow) 
remaining moderately hyperintense at 180 seconds (b, arrow). Two hours after the injection of gadobenate dimeglumine (c), lesion shows contrast uptake 
appearing hyperintense in comparison to the surrounding liver parenchyma, confirming its hepatocellular nature (arrow). After the administration of 







Table 2. Qualitative analysis of 21 FNHs at contrast-enhanced MRI
Arterial Portal–venous 180 seconds Hepatobiliary
Gadobenate dimeglumine 
(n=21)
Hyperintense (n=21, 100%) Hyperintense (n=14, 66%) 
Isointense (n=7, 33%)
Hyperintense (n=14, 67%) 
Isointense (n=7, 33%)
Hyperintense (n=12, 57%) 
Isointense (n=5, 24%) 
Ring-like (n=4, 19%) 
Gadoxetate disodium (n=21) Hyperintense (n=21, 100%) Hyperintense (n=15, 71%) 
Isointense (n=6, 29%)
Hyperintense (n=12, 57%) 
Isointense (n=8, 38%) 
Slightly hypointense (n=1, 5%)
Hyperintense (n=8, 38%) 
Isointense (n=8, 38%) 
Ring-like (n=5, 24%)
(n=4) after gadobenate dimeglumine and 
hypointense (n=10) after gadoxetate diso-
dium;
In the hepatobiliary phase: a) hypointense 
(n=14) after gadobenate dimeglumine and 
hypointense (n=10) after gadoxetate diso-
dium.
No statistically significant differences 
were observed in the detection and the im-
aging features of the central scar after the 
injection of the two contrast media during 
the arterial (P = 0.564), portal-venous 
(P = 0.607) phases, at 180 s (P = 0.172), and 
during the hepatobiliary phase (P = 0.572).
No statistically significant differences 
were found in SIR after either gadobenate 
dimeglumine and gadoxetate disodium 
administration during all enhanced phases 
except for hepatobiliary phase in which 
SIR was higher after gadoxetate disodium 
(P = 0.048) (Table 3).
No statistically significant differences 
were found in CRFNH-to-liver after either gado-
benate dimeglumine and gadoxetate di-
sodium administration during the arterial 
(P = 0.485) and portal-venous (P = 0.360) 
phases and at 180 s (P = 0.936), respective-
ly. CRFNH-to-liver resulted significantly higher 
after gadoxetate disodium than after gado-
benate dimeglumine during hepatobiliary 
phase (P = 0.032) (Table 4).
Liver parenchyma SI gain on hepatobili-
ary phase resulted significantly higher for 
gadoxetate disodium (P = 0.012) (Table 5). 
Discussion 
In this study we performed an intraindi-
vidual comparison of 21 FNH lesions after 
the injection of gadobenate dimeglumine 
and gadoxetate disodium, the two hepa-
tobiliary contrast agents that are currently 
available in the market. We found that the 
dynamic and hepatobiliary enhancement 
patterns of FNH do not significantly differ 
when either contrast agent is injected. Ho-
mogeneous iso-hyperintensity on hepa-
tobiliary phase was noted in similar per-
centages after injection of either contrast 
agents (gadobenate dimeglumine, 81% vs. 
gadoxetate disodium, 76%). 
We did not find any statistically signif-
icant difference between gadobenate 
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Figure 2. a–f. FNH in a 43-year-old woman. After gadobenate dimeglumine injection in the arterial phase (a), a 2.1 cm sized lesion shows a bright 
and homogeneous contrast enhancement (arrow) except for a central hypointense area corresponding to the central scar (arrowhead). FNH appears 
hyperintense at 180 seconds (b, arrow), whereas the central scar is hypointense (arrowhead). Two hours after the injection of gadobenate dimeglumine 
(c), the lesion shows a ring-like pattern. After the administration of gadoxetate disodium (d–f), similar findings are observed in the arterial (d), 180 
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dimeglumine and gadoxetate disodium in 
central scar detection in any of the phases. 
However, at 180 s the central scar showed 
enhancement in 5 cases after gadobenate 
dimeglumine administration, while it was 
hypointense after gadoxetate disodium ad-
ministration. This could be explained with 
the prolonged extravascular interstitial 
phase and a delayed hepatocyte uptake of 
gadobenate dimeglumine in comparison to 
gadoxetate disodium. These data are simi-
lar to those reported by Karam et al. (13).
We noted some statistically significant 
differences in the quantitative analysis 
regarding: 1) SIR of FNHs (P = 0.048), 2) 
CR FNH-to-liver (P = 0.032), and 3) parenchymal 
SI gain (P = 0.012) on hepatobiliary phase 
in favor of gadoxetate disodium. These 
data could be explained with the different 
percentage of contrast media uptake by 
hepatocytes and excretion into the biliary 
system (50% for gadoxetate disodium vs. 
3%–5% for gadobenate dimeglumine) (14). 
Gupta et al. (15) reported results similar to 
ours on 30 patients with FNHs who under-
went both gadobenate dimeglumine and 
gadoxetate disodium enhanced MRI, in 
particular regarding SI ratio and CRFNH-to-liver. 
However, they noted that SIR values were 
higher in the portal phase after gadobenate 
dimeglumine than after gadoxetate disodi-
um, whereas we did not observe any statis-
tically significant difference. This different 
result could be due to the lack of standard-
ization of the dose of gadoxetate disodium 
and to the multicentric nature of their study 
that implied some protocol variability, 
whereas we correlated the dose of contrast 
with patient’s weight and conducted a sin-
gle institution study (15). 
Despite our findings indicate some statis-
tically significant difference on hepatobili-
ary phase between the two contrast media 
at quantitative evaluation, FNHs did not 
show any difference at qualitative analysis. 
Consequently, on the basis of widely known 
diagnostic imaging criteria for FNH, these 
differences do not compromise the final di-
agnosis. The only difference between these 
two contrast agents is the length of the ex-
amination: approximately 30 minutes with 
gadoxetate disodium, longer with gado-
benate dimeglumine because the hepa-
tobiliary phase is acquired 1–3 hours after 
contrast injection. This difference should be 
considered to appropriately manage MRI 
unit daily routine. 
Finally, FNHs showed a ring-like appear-
ance on the hepatobiliary phase after ad-
ministration of gadobenate dimeglumine 
in four cases and after gadoxetate disodi-
um in five cases. On this regard, it has been 
demonstrated that, after the injection of 
gadoxetate disodium, a minority of FNH le-
sions can show this peculiar ring pattern of 
enhancement on the hepatobiliary phase, 
and the explanation is the higher expres-
sion of uptake transporter OATP1B3 (organ-
ic anion transporter polypeptide) on the 
membrane of the sinusoidal side of those 
hepatocytes located in the periphery of the 
lesion in comparison to the relative scarcity 
of OATP1B3 receptors on those hepatocytes 
located in the center of FNH lesions (8). Al-
though we do not have pathologic proof to 
confirm our hypothesis, we speculate that 
this could be the explanation for our find-
ings as well (7, 9, 16–19).
Our study presents some limitations. 
First, we had a selection bias. Our patients 
were selected on the basis of their pre-
Table 3. Signal intensity ratios of 21 FNHs
SIR Arterial Portal-venous 180 seconds Hepatobiliary
Gadobenate dimeglumine 127.5 (108.6–150.7) 148.4 (120.6–160.5) 123.8 (105.4–150.7) 117.5 (84.4–140.5)
Gadoxetate disodium 112.2 (0.7–144.6) 115.3 (93.6–169.1) 117.6 (106.5–152.7) 140.2 (124.9–157.1)
P 0.405 0.336 0.996 0.048
Data are presented as median and interquartile range (Q1–Q3).
SIR, signal intensity ratio.
Table 4. Lesion-to-liver contrast ratio of 21 FNHs
Lesion-to-liver contrast ratio Arterial Portal-venous 180 seconds Hepatobiliary
Gadobenate dimeglumine 19.9 (14.5–25.8) 8.0 (3.7–11.6) 8.1 (0.9–10.7) 0.1 (-3.8 to 4.1)
Gadoxetate disodium 20.8 (11.1–27.0) 7.2 (5.5–9.8) 4.8 (0.2–8.2) 0.7 (-1.8 to 5)
P 0.485 0.360 0.936 0.032
Data are presented as median and interquartile range (Q1–Q3).
Table 5. Liver parenchyma SI gain on hepatobiliary phase
SI gain Hepatobiliary
Gadobenate dimeglumine 104.7 (61.7–119.0)
Gadoxetate disodium 119.2 (99.0–133.1)
P 0.012
Data are presented as median and interquartile range (Q1–Q3).
SI, signal intensity.
sumed diagnosis in an imaging database. 
Consequently, those with FNH lesions lack-
ing all typical imaging findings were not 
included. We acknowledge that this selec-
tion bias reduces the value of our study, as 
atypical FNH would be the lesions for which 
optimising imaging would be most import-
ant. Nevertheless, this bias would not have 
affected both gadobenate dimeglumine or 
gadoxetate disodium MRI scan. Second, a 
final diagnosis was not established by his-
tological evaluation. However, since our 
patients did not have history of chronic 
liver disease or known malignancy, the di-
agnosis of FNH was obtained when clinical, 
biochemical, and imaging criteria were met. 
The differential diagnosis between arterio-
portal shunting and FNH can be challeng-
ing, because these observations are both 
hypervascular in the hepatic arterial phase 
and tend to fade to isointensity on portal 
venous phase. However, FNH is typically 
round or oval in shape, while arterove-
nous shunting is usually triangular and in 
a subcapsular location. Whatever the na-
ture, when hypervascular observations are 
smaller than 1 cm, differential diagnosis can 
be very tough, although clinically irrelevant 
in patients with no chronic liver disease or 
other risk factors (i.e., extrahepatic tumor). 
Third, imaging analysis was performed by 
consensus and interobserver agreement 
was not assessable. Finally, our study pop-
ulation is limited due to the intraindividual 
comparison in a single department be-
tween two different contrast media. 
In conclusion, there were no significant 
differences in the MRI findings of FNH af-
ter the injection of a weight-based dose of 
either gadobenate dimeglumine or gadox-
etate disodium.  
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